N※N

FDA to Revisit Moderna's mRNA Flu Vaccine

  //food-wine.news-articles.net/content/2026/02/18/fda-to-revisit-moderna-s-mrna-flu-vaccine.html
  Published in Food and Wine on Wednesday, February 18th 2026 at 23:38 GMT by nbcnews.com
      Locales: Maryland, UNITED STATES

Washington D.C. - February 19th, 2026 - In a significant development for preventative healthcare and mRNA technology, the Food and Drug Administration (FDA) announced today it will revisit its previous decision and begin a full review of Moderna's mRNA-based influenza vaccine, designated mRNA-1011. This reversal comes after the agency initially declined to approve the vaccine in March of 2025, citing manufacturing concerns.

The news offers a potential boost to Moderna's ambitious plans to utilize mRNA technology beyond COVID-19, and could revolutionize the way seasonal influenza is tackled. Initial clinical trials of mRNA-1011 showed remarkably promising results, demonstrating a significantly improved antibody response compared to traditional, egg-based flu vaccines currently on the market.

While the FDA's initial rejection in March 2025 raised eyebrows among industry observers, the agency stressed at the time that the decision wasn't related to the vaccine's efficacy, but rather to inconsistencies identified in Moderna's manufacturing processes. These inconsistencies, though not deemed a safety risk, highlighted a need for greater control and standardization in the production of the complex mRNA vaccine.

"The FDA's commitment remains steadfast: to protect and enhance public health through rigorous evaluation of all medical products," stated Dr. Eleanor Vance, a spokesperson for the FDA, in a press conference this morning. "Following the initial decision, Moderna provided supplementary data addressing our concerns regarding manufacturing consistency. Our team of experts will now thoroughly analyze this information to determine if mRNA-1011 meets the FDA's stringent standards for safety, efficacy, and quality."

Moderna officials have expressed optimism about the FDA's decision. "This is a positive step forward not only for Moderna, but for the entire field of mRNA medicine," said Stephane Bancel, CEO of Moderna, in a released statement. "We've been diligently working to refine our manufacturing processes and provide the FDA with the comprehensive data they requested. We are confident that mRNA-1011 holds the potential to significantly improve flu prevention rates and reduce the burden of seasonal influenza."

Beyond the Flu: Moderna's Multi-Disease mRNA Platform

The mRNA-1011 vaccine is a cornerstone of Moderna's larger strategy to develop a suite of mRNA-based vaccines targeting a variety of common respiratory illnesses. The success of its COVID-19 vaccine demonstrated the speed and flexibility of the mRNA platform, allowing for rapid development and deployment of vaccines in response to emerging threats. The company is currently pursuing mRNA vaccines for Respiratory Syncytial Virus (RSV), and continues to explore potential vaccines for other infectious diseases.

Experts believe that an effective mRNA flu vaccine could offer several advantages over traditional flu vaccines. Current flu vaccines require months of lead time for production, relying on predicting which flu strains will be dominant each season. This prediction isn't always accurate, leading to reduced vaccine efficacy. mRNA technology, however, allows for faster adaptation to new strains and potentially combined vaccines that offer broader protection. The initial trial data for mRNA-1011 indeed hinted at effectiveness against a wider range of flu strains than conventional vaccines.

"The potential for a broadly protective flu vaccine is huge," explains Dr. Anya Sharma, an infectious disease specialist at the National Institutes of Health. "If Moderna can consistently produce a vaccine that triggers a strong immune response against multiple flu strains, it could significantly reduce the severity and spread of seasonal influenza. The manufacturing hurdles are significant, but the potential benefits are well worth overcoming them."

The FDA review process is expected to take several months. The agency will scrutinize the data provided by Moderna, including details of the manufacturing process, clinical trial results, and safety data. If approved, mRNA-1011 could be available to the public as early as the 2026-2027 flu season, offering a new weapon in the fight against this persistent public health challenge. The agency is expected to convene an advisory committee of independent experts to review the data and provide recommendations before a final decision is made.